Ocular adverse events of molecularly targeted agents approved in solid tumours: A systematic review

Huillard, Olivier; Bakalian, S.; Lévy, Christine; Desjardins, Laurence; Rouic, Livia Lumbroso‐Le; Pop, Simona; Sablin, Marie‐Paule; Tourneau, Christophe Le

doi:10.1016/j.ejca.2013.10.016

Cited by 72 publications

(56 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Typically, inflammation, conjunctivitis, and blepharitis occur early in therapy (around week 3), and trichomegaly rarely occurs before weeks 8–12 of therapy (Fraunhelder & Fraunhelder, 2012). EGFR TKIs responsible for this toxicity include erlotinib (Tarceva ® ) and gefitinib (Iressa ® ); lapatinib (Tykerb ® ), also an EGFR inhibitor, has not been associated with ocular adverse events, which is potentially related to less selective targeting or underreporting of toxicity (Huillard et al, 2014). …”

Section: Molecular Targets and Ocular Effectsmentioning

confidence: 99%

“…Keratitis is an inflammation of the cornea, often beginning with the erosion of the epithelial surface (Huillard et al, 2014). The epithelial cells control corneal hydration; targeted agents can decrease proliferation of these corneal epithelial cells, which can lead to delay in wound healing and scarring.…”

Section: Effects On the Eyementioning

confidence: 99%

“…Damage to the ocular surfaces, retina, cornea, and optic nerve can be temporary or permanent. Ocular side effects are not uncommon with cytotoxic chemotherapy, but they are rarely severe or dose limiting (Huillard et al, 2014). However, serious toxicity has been associated with molecularly targeted cancer therapies, particularly tyrosine kinase inhibitors (TKIs).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Ocular Toxicity of Tyrosine Kinase Inhibitors

Davis¹

2016

ONF

View full text Add to dashboard Cite

Purpose/Objectives To review common tyrosine kinase inhibitors, as well as their ocular side effects and management. Data Sources A comprehensive literature search was conducted using cINahl®, Pubmed, and cochrane databases for articles published since 2004 with the following search terms: ocular toxicities, tyrosine kinase inhibitors, ophthalmology, adverse events, eye, and vision. Data Synthesis Tyrosine kinase inhibitors can cause significant eye toxicity. Conclusions Given the prevalence of new tyrosine kinase inhibitor therapies and the complexity of possible pathogenesis of ocular pathology, oncology nurses can appreciate the occurrence of ocular toxicities and the role of nursing in the management of these problems. Implications for Nursing Knowledge of the risk factors and etiology of ocular toxicity of targeted cancer therapies can guide nursing assessment, enhance patient education, and improve care management. Including a review of eye symptoms and vision issues in nursing assessment can enhance early detection and treatment of ocular toxicity.

show abstract

Section: Molecular Targets and Ocular Effectsmentioning

confidence: 99%

Section: Effects On the Eyementioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Ocular Toxicity of Tyrosine Kinase Inhibitors

Davis¹

2016

ONF

View full text Add to dashboard Cite

show abstract

“…Most EGFR inhibitors cause blepharitis and lacrimation disorders, with the exception of lapatinib, for which no ocular adverse effects have been reported 25,165,166 . C-kit inhibitors, which include imatinib, pazopanib, sunitinib, can cause orbital and periorbital oedema, although systemic use of VEGF pathway inhibitors rarely cause direct ocular defects 30,173,174 . The visual syndromes observed with VEGF/VEGFR inhibitors tend to be related to cardiovascular or thromboembolic toxicities 174 .…”

Section: Ocular Toxicitiesmentioning

confidence: 99%

“…Ocular toxicities with targeted agents range from mild symptoms, such as blurred vision, altered light perception, conjunctivitis, to severe vision impairement, such as corneal erosion, ulcer, perforation, optic neuritis, vitreous haemorrhage, retinal detachment, and retinal vascular occlusion 173 . Most EGFR inhibitors cause blepharitis and lacrimation disorders, with the exception of lapatinib, for which no ocular adverse effects have been reported 25,165,166 .…”

Section: Ocular Toxicitiesmentioning

confidence: 99%

Kinase inhibitors and monoclonal antibodies in oncology: clinical implications

2015

View full text Add to dashboard Cite

Molecularly targeted cancer therapies, such as small-molecule kinase inhibitors and monoclonal antibodies, constitute a rapidly growing and an important part of the oncology armamentarium. Unlike conventional (cytotoxic) chemotherapeutics, targeted therapies were designed to disrupt cancer cell pathogenesis at specific biological points essential for the development and progression of the tumour. These agents were developed to disrupt specific targets with the aim of minimizing treatment burden compared with conventional chemotherapy. Nevertheless the increasingly common use of targeted therapies has revealed some unanticipated, often clinically significant toxic effects, as well as compromising effective palliative and end-of-life management approaches. Although patients and clinicians welcome improvements in cancer prognosis, these changes can also impact patient quality-of-life. Therefore, as demand for oncology expertise increases, physicians need to apprise themselves of targeted therapies and their clinical implications, including drug-specific side effects, impact on quality of life, and cost issues, especially in relation to end-of-life care. This Review provides a useful summary and guide for professionals treating patients with malignant diseases.

show abstract

Epidermal Growth Factor Receptor Inhibitors for Lung Cancer and the Risk of Keratitis

Huang,

Lin,

Dana

et al. 2024

JAMA Ophthalmol

View full text Add to dashboard Cite

ImportanceEpidermal growth factor receptor inhibitors (EGFRis) have been reported to be associated with cutaneous and ocular side effects; however, there is limited evidence of an association between EGFRi treatment and keratitis.ObjectiveTo determine the association between EGFRi treatment and agents and the risk of new-onset keratitis among patients with lung cancer.Design, Setting, and ParticipantsThis US population–based cohort study examined TriNetX data of patients with lung cancer treated with or without EGFRis between May 1, 2003, and October 30, 2023.ExposuresTreatment with EGFRis, including the first-generation agents gefitinib and erlotinib, the second-generation agent afatinib, and the third-generation agent osimertinib.Main Outcomes and MeasuresThe risk of new-onset keratitis among patients with lung cancer receiving EGFRi treatment was determined using logistic and Cox proportional hazards regression.ResultsAmong 1 388 108 patients with lung cancer, 22 225 received EGFRis (mean [SD] age, 69.7 [10.6] years; 62.8% females and 37.2% males). Patients treated with EGFRis had a higher risk of keratitis than nonexposed patients (hazard ratio [HR], 1.520; 95% CI, 1.339-1.725). Subtypes of EGFRi-associated keratitis included keratoconjunctivitis (HR, 1.367; 95% CI, 1.158-1.615), superficial keratitis (HR, 1.635; 95% CI, 1.306-2.047), and corneal ulcer (HR, 2.132; 95% CI, 1.515-3.002). Patients taking afatinib had a higher risk of keratitis (HR, 2.229; 95% CI, 1.480-3.356).Conclusions and RelevanceThese findings suggest that patients with lung cancer treated with EGFRis may have an increased risk of new-onset keratitis, especially with the second-generation EGFRi afatinib, supporting the need for prompt diagnosis and management of EGFRi-associated ocular issues to prevent serious complications or treatment disruptions.

show abstract

Ocular adverse events of molecularly targeted agents approved in solid tumours: A systematic review

Cited by 72 publications

References 55 publications

Ocular Toxicity of Tyrosine Kinase Inhibitors

Ocular Toxicity of Tyrosine Kinase Inhibitors

Kinase inhibitors and monoclonal antibodies in oncology: clinical implications

Epidermal Growth Factor Receptor Inhibitors for Lung Cancer and the Risk of Keratitis

Contact Info

Product

Resources

About